Latest Interim Financial Report News

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Infragreen launches a strategic review revealing a $10 million on-market buyback and potential asset sales to address significant undervaluation despite strong FY26 growth forecasts.

Papyrus Australia has commissioned its Adelaide Rapid Prototyping & R&D Facility, marking a key step in validating its pulp technology and progressing towards commercial production. The company also released its interim financials and reported stable cash flow supporting ongoing operations.

Temas Resources Corp has opted to reduce its financial reporting frequency, moving from quarterly to semi-annual reports under a Canadian Securities Exchange pilot program. This change aligns with its status as a venture issuer and reflects its ongoing focus on proprietary processing technology and mineral projects.

NeuRizer Limited has secured a pivotal partnership with Reliance Industries, enabling it to resolve funding challenges and accelerate its Leigh Creek urea project. This collaboration marks a turning point for the company, allowing it to exit suspension and advance critical regulatory and operational milestones.

Complii FinTech Solutions reported a $1.35 million loss for H1 FY26 alongside a 6% increase in annual recurring revenue, driven by strategic platform upgrades and expanding client engagement.

Norwood Systems Limited reported a significant revenue increase for the half-year ended December 2025, alongside a widening net loss and strategic progress with Tier-1 telecom customers. The company secured additional funding and advanced its AI-driven voice platforms in collaboration with global hyperscalers.

Excelsior Capital Limited reported a $2.08 million loss for the half-year ending December 2025 as it moves to wind up operations, yet declared a substantial fully franked interim dividend.

Verbrec Limited has reported a remarkable turnaround in its half-year results, posting a $9 million net profit and announcing its first interim dividend in the current period. Strategic acquisitions and a sharp rise in net tangible assets underpin this strong performance.

Echo IQ Limited reported a modest revenue increase for the half-year ended December 2025, yet its net loss widened significantly, raising questions about its path to profitability.

Pentanet Limited has reported a solid half-year performance for the period ending 31 December 2025, with revenue growth and a significant surge in EBITDA, while narrowing its net loss. Both its Telecommunications and Gaming segments contributed to the improved results, supported by subscriber growth and operational efficiencies.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.